Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Pegatron | Pfizer | |
|---|---|---|
| Moat rating | none The 2025 annual report (English version filed with TWSE on 2026-05-08) shows scale without a protected position. Consolidated revenue was NT$1,117.2 billion, down from NT$1,125.3 billion, at a gross margin of 3.80%, while DigiTimes put the top 20 EMS/ODM vendors' combined 2025 revenue up 23.4% in US dollars (cnyes, 2026-02-02). One coded customer ("A Company") took 57.34% of 2025 net sales (59.34% in 2024) and a second ("B Company") 9.14%, and the report lists "Intense Competition and Pricing Pressure" and "Customer Concentration and Product Cycle Risks" among its disadvantages. A DigiTimes analysis of the 2024 top 20 (2025-01-27) found Pegatron's net-profit rank six places below its revenue rank, and its net margin at 1.5% or less since 2018 with no clear sign of improvement. A large assembler whose own report and independent data describe no protected return: no moat is claimable. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | none The report's listed competitive advantages are operating capabilities that rivals also have: 4,997 R&D engineers, manufacturing sites in China, the USA, Mexico, the Czech Republic, Indonesia, Vietnam, Malaysia, India and Taiwan, a diversified product and customer base, global logistics, an experienced management team, and vertical integration across materials from metal stamping and plastic injection to light-metal technologies. R&D was 1.44% of 2025 revenue, and the supplier table notes that "partial major materials are purchased by major customers and resell to the Company for manufacturing and system assembly". Its seat in Apple's supply chain has proved contestable: DigiTimes (via Global SMT, 2025-07-24) says Chinese vendors, "most notably Luxshare, have gained ground through acquisitions and key contract wins, including major entries into Apple's supply chain via asset purchases from Merry Electronics, Lite-On, Wistron, and Pegatron". DigiTimes' analyst wrote (2025-01-27) that Pegatron, Wistron, Compal and Inventec all began as computer-system makers whose component businesses and degree of vertical integration can hardly match those of Chinese makers. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | behind DigiTimes' July 2025 ranking (via Global SMT, 2025-07-24) says "Pegatron had long held the second spot" until Quanta overtook it in 1H24, that "Luxshare displaced Pegatron to become the No. 3 EMS/ODM vendor in the second half of 2024", and ranks it fourth in 1H25 after Wistron's surge. DigiTimes' 2025 full-year ranking (cnyes, 2026-02-02) lists the top five in order as Foxconn, Wistron, Quanta, Luxshare and Pegatron. In notebooks, market research cited in the annual report puts Pegatron fifth of the five Taiwanese ODMs it lists, at 9.1 million units or 4.96% of worldwide volume. Its 2025 revenue fell 0.73% in NT dollars (annual report) while DigiTimes put Foxconn's up 22.4% and Quanta's up 55.6% in US dollars (cnyes), and 1H26 revenue fell again, by 3.9% to NT$518,553 million (2Q26 business review): losing ground to peers, so behind rather than at parity. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | weak The annual report gives a 2025 gross margin of 3.80%, with gross profit down 7.67% on net sales down 0.73%; the 2Q26 business review shows 1H26 gross margin of 4.4% against 3.4% a year earlier. Among its disadvantages the report says "increasing competition may place pressure on pricing and profitability". DigiTimes (2025-01-27) counted Pegatron among Taiwanese makers whose net margin had been 1.5% or less since 2018, with no clear sign of improvement. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Pegatron is a Taiwanese EMS/ODM whose 2025 annual report describes three segments: computing (notebooks, desktops, motherboards, servers), communication (cable modems, set-top boxes, smartphones, switches, routers, gateways, 5G O-RAN) and consumer electronics (tablets, game consoles, wearables, smart home devices, automotive electronics). Communication remained the largest segment in 2025, and one coded customer took 57.34% of net sales. Revenue was NT$1,117.2 billion at a 3.80% gross margin. Servers are the growth line: the report cites large-scale shipments of NVIDIA GB300 NVL72 and HGX B300 systems in 2025, and the 2Q26 business review (2026-08-12) says computing revenue rose 84% year on year, "driven mostly by greater shipment from Server business", taking computing to 23% of revenue while communication fell to 52% after a double-digit decline. Independent rankings show it losing ground: DigiTimes says Pegatron "had long held the second spot" among EMS/ODM vendors by revenue until Quanta passed it in 1H24, and its 2025 full-year ranking puts it fifth behind Foxconn, Wistron, Quanta and Luxshare, with 2026 AI server and rack orders expected to concentrate in Foxconn, Wistron and Quanta. Gross margin improved to 4.4% in 1H26 from 3.4% a year earlier, still thin. A large, diversified assembler without a protected position. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Contract designer-manufacturer for brand customers in computing, communication and consumer electronics; America took 41.18% and Europe 38.79% of 2025 sales, and some major materials are bought by major customers and resold to Pegatron for assembly (annual report). | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
| Long-horizon vote | -0.20 at weight 0.20 · swarm bearish Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |